FindTrial
Sign In

NOAC

DRUG7 trials

Sponsors

Charles University, Czech Republic, Population Health Research Institute, Duk-Woo Park, MD, Boehringer Ingelheim, Attikon Hospital

Conditions

Aortic Valve StenosisAtrial FibrillationCoronary Artery DiseaseIntracerebral HemorrhageIschemic StrokeStroke

Phase 2

NOACs for Stroke Prevention in Patients With Atrial Fibrillation and Previous ICH
CompletedNCT02998905
Population Health Research InstituteAtrial Fibrillation, Intracerebral Hemorrhage
Start: 2017-04-26End: 2020-02-18Updated: 2020-03-20

Phase 4

Left Atrial Appendage Closure vs. Novel Anticoagulation Agents in Atrial Fibrillation
CompletedNCT02426944
Charles University, Czech RepublicAtrial Fibrillation
Start: 2015-10-13End: 2019-07-20Target: 400Updated: 2021-06-11
Anticoagulant Versus Dual Antiplatelet Therapy for Preventing Leaflet Thrombosis and Cerebral Embolization After Transcatheter Aortic Valve Replacement
CompletedNCT03284827
Duk-Woo Park, MDAortic Valve Stenosis
Start: 2018-03-15End: 2021-11-05Updated: 2021-11-08

Unknown Phase

This Study Observes the Use of New Oral Anticoagulants (NOACs) in Patients With a Heart Rhythm Disorder in Spain
CompletedNCT03285373
Boehringer IngelheimAtrial Fibrillation
Start: 2017-11-29End: 2019-01-31Updated: 2020-02-18
The Greek AntiPlatElet Atrial Fibrillation Registry.
CompletedNCT03362788
Attikon HospitalAtrial Fibrillation, Coronary Artery Disease
Start: 2017-12-01End: 2020-12-31Updated: 2021-07-26
Left Atrial Appendage Occlusion Versus Novel Oral Anticoagulation for Stroke Prevention in Atrial Fibrillation
RecruitingNCT03642509
University of AarhusAtrial Fibrillation, Stroke
Start: 2019-01-01End: 2030-10-01Target: 750Updated: 2023-12-21
Complex Percutaneous Pulmonary Vein Isolation Combined With Left Atrial Appendage Occluder Implantation for Patients With Cardiogenic Ischemic Stroke in the Course of Atrial Fibrillation
Not yet recruitingNCT06212674
Medical University of SilesiaAtrial Fibrillation, Ischemic Stroke
Start: 2024-01-31End: 2029-08-31Target: 240Updated: 2024-01-24

Related Papers

Effect of cerebral embolic protection device on new cerebral embolism during transcatheter aortic valve replacement: A prospective sentinel registry.
2025-08-14
Pulsed field ablation vs sham ablation to treat atrial fibrillation (the PFA-SHAM trial)
Heart Rhythm O22025-08-071 citations
Frequency, Predictors, and Clinical Impact of Valvular and Perivalvular Thrombus After Transcatheter Aortic Valve Replacement.
2023-12-0112 citations
Effects of oral anticoagulation in people with atrial fibrillation after spontaneous intracranial haemorrhage (COCROACH): prospective, individual participant data meta-analysis of randomised trials.
2023-10-1238 citations
Impact of leaflet thrombosis on valve haemodynamic status after transcatheter aortic valve replacement
Heart2023-08-166 citations
Edoxaban Versus Dual Antiplatelet Therapy for Leaflet Thrombosis and Cerebral Thromboembolism After TAVR: The ADAPT-TAVR Randomized Clinical Trial
Circulation2022-04-0486 citations
4-Year Outcomes After Left Atrial Appendage Closure Versus Nonwarfarin Oral Anticoagulation for Atrial Fibrillation.
2021-11-05189 citations
Rationale and design of the ADAPT-TAVR trial: a randomised comparison of edoxaban and dual antiplatelet therapy for prevention of leaflet thrombosis and cerebral embolisation after transcatheter aortic valve replacement
BMJ Open2021-01-0112 citations
Trends of Antithrombotic Treatment in Atrial Fibrillation Patients Undergoing Percutaneous Coronary Intervention: Insights from the GReek-AntiPlatElet Atrial Fibrillation (GRAPE-AF) Registry.
2020-10-096 citations
Left Atrial Appendage Closure Versus Direct Oral Anticoagulants in High-Risk Patients With Atrial Fibrillation.
2020-06-01424 citations
Oral anticoagulant re-initiation following intracerebral hemorrhage in non-valvular atrial fibrillation: Global survey of the practices of neurologists, neurosurgeons and thrombosis experts.
2018-01-2516 citations